Department of Urologic Surgery, The First Affiliated Hospital and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003 Henan, China.
Dis Markers. 2022 May 13;2022:6758595. doi: 10.1155/2022/6758595. eCollection 2022.
Currently, lots of scholars have proved that the expression of NCAPG is associated with the prognosis of several cancers, while the relationship between NCAPG and renal clear cell carcinoma remains unclear, so the main aim of this research is to explore the effects of NCAPG on the progression of renal clear cell carcinoma.
We observed the differential expression of NCAPG in several cancers from GEPIA online database, and the expression of NCAPG in renal clear cell carcinoma and normal tissue was compared and further verified by IHC assay. CCK-8 assay and clone formation experiment were conducted to observe the change of NCAPG on the proliferation. GraphPad was used for data analysis, and -test and analysis were used to analyze the correlation between NCAPG/CDK1 and renal clear cell carcinoma.
NCAPG was upregulated in renal clear cell carcinoma compared with the normal tissue, and the expression of NCAPG was associated with the clinical prognosis of pancreatic cancer especially with tumor size ( = 0.010). Knockdown NCAPG could restrain the proliferation of renal clear cell carcinoma. CDK1 was found to be tightly related with NCAPG, and the expression of CDK1 was also associated with the prognosis.
NCAPG was upregulated in renal clear cell carcinoma, which was related with tumor size and overall survival. NCAPG might promote the proliferation of renal clear cell carcinoma via mediating CDK1. NCAPG/CDK1 complex might provide a new treatment strategy for lots of patients with renal clear cell carcinoma.
目前，许多学者已经证明 NCAPG 的表达与几种癌症的预后有关，而 NCAPG 与肾透明细胞癌之间的关系尚不清楚，因此本研究的主要目的是探讨 NCAPG 对肾透明细胞癌进展的影响。
我们从 GEPIA 在线数据库观察了 NCAPG 在几种癌症中的差异表达，并通过免疫组化检测比较和进一步验证了 NCAPG 在肾透明细胞癌和正常组织中的表达。通过 CCK-8 检测和克隆形成实验观察 NCAPG 对增殖的变化。使用 GraphPad 进行数据分析，使用 t 检验和 分析来分析 NCAPG/CDK1 与肾透明细胞癌之间的相关性。
与正常组织相比，NCAPG 在肾透明细胞癌中上调，并且 NCAPG 的表达与胰腺癌的临床预后特别是与肿瘤大小相关（ = 0.010）。敲低 NCAPG 可抑制肾透明细胞癌的增殖。发现 CDK1 与 NCAPG 紧密相关，并且 CDK1 的表达也与预后相关。
NCAPG 在肾透明细胞癌中上调，与肿瘤大小和总生存期相关。NCAPG 可能通过介导 CDK1 促进肾透明细胞癌的增殖。NCAPG/CDK1 复合物可能为许多肾透明细胞癌患者提供新的治疗策略。
